Financial Performance - Revenue for the third quarter was RMB 266.84 million, a year-on-year increase of 29.88%[8] - Net profit attributable to shareholders of the listed company was RMB 108.90 million, up 26.85% year-on-year[8] - Revenue for the first nine months was RMB 888.46 million, a year-on-year increase of 33.75%[8] - Net profit attributable to shareholders of the listed company for the first nine months was RMB 388.43 million, up 29.10% year-on-year[8] - Net profit attributable to parent company shareholders reached RMB 388.43 million, an increase from RMB 300.88 million in the previous year[39] - Operating profit rose to RMB 453.22 million, compared to RMB 349.19 million in the prior year[36] - Sales revenue from goods and services reached RMB 937.02 million, up from RMB 736.26 million, marking a 27.3% increase[41] - Basic earnings per share for the quarter were RMB 1.52, a year-on-year increase of 27.73%[12] - Basic earnings per share (EPS) increased to RMB 5.40, up from RMB 4.18 in the previous year[41] - Total comprehensive income attributable to parent company shareholders was RMB 388.04 million, compared to RMB 300.88 million in the prior year[39] R&D Investment - R&D investment for the quarter was RMB 59.83 million, accounting for 22.42% of revenue, an increase of 1.86 percentage points year-on-year[12] - R&D investment for the first nine months was RMB 180.61 million, accounting for 20.33% of revenue, an increase of 4.95 percentage points year-on-year[12] - R&D expenses increased to RMB 117.77 million, up from RMB 88.18 million, reflecting a 33.5% year-over-year growth[36] Cash Flow and Liquidity - Operating cash flow for the first nine months was RMB 327.81 million, up 24.38% year-on-year[12] - Net cash flow from operating activities was RMB 327.81 million, an increase from RMB 263.54 million in the previous year[41] - Investment activities resulted in a net cash outflow of RMB 630.71 million, compared to RMB 323.23 million in the prior year[44] - Cash and cash equivalents at the end of the period stood at RMB 489.09 million, down from RMB 1,017.14 million in the previous year[44] Asset and Liability Position - Total assets as of the end of the reporting period were RMB 2.28 billion, an increase of 14.24% compared to the end of the previous year[12] - Total assets increased to 2,279,267,950.44 RMB, up from 1,995,118,702.47 RMB[50] - Non-current assets totaled 788,001,416.59 RMB, compared to 700,775,988.75 RMB[50] - Current liabilities rose to 242,124,052.40 RMB, up from 186,834,939.68 RMB[50] - Non-current liabilities decreased to 61,465,229.77 RMB, down from 65,659,229.72 RMB[50] - Accounts payable increased to 47,739,636.27 RMB, up from 42,129,528.43 RMB[50] - Contract liabilities slightly increased to 2,597,745.23 RMB, compared to 2,525,850.68 RMB[50] - Employee benefits payable decreased to 44,711,235.95 RMB, down from 57,457,439.28 RMB[50] - Taxes payable surged to 31,159,415.38 RMB, up from 10,555,141.32 RMB[50] - Other payables increased to 93,607,982.61 RMB, up from 56,048,531.87 RMB[50] - Lease liabilities decreased to 27,668,706.91 RMB, down from 32,086,974.44 RMB[50] Shareholder Information - MicroPort Endovascular CHINA Corp. Limited holds 32,902,933 shares, representing 45.71% of the total shares[20] - National Social Security Fund 406 holds 1,918,756 shares, accounting for 2.67% of the total shares[20] - Shanghai Honghao Investment Management Center holds 1,440,300 shares, representing 2.00% of the total shares[20] - National Social Security Fund 413 holds 1,384,598 shares, accounting for 1.92% of the total shares[20] - Bank of China - Huabao CSI Medical ETF holds 1,020,130 shares, representing 1.42% of the total shares[20] - Hong Kong Securities Clearing Company holds 783,709 shares, accounting for 1.09% of the total shares[20] - Basic Pension Fund 16052 holds 523,876 shares, representing 0.73% of the total shares[20] - Basic Pension Fund 1202 holds 509,456 shares, accounting for 0.71% of the total shares[20] - MicroPort Investment Holding Co., Ltd. holds 450,000 shares, representing 0.63% of the total shares[20] - Agricultural Bank of China - ICBC Credit Suisse Strategic Transformation Fund holds 388,565 shares, accounting for 0.54% of the total shares[20] Profitability Metrics - Weighted average return on equity (ROE) for the quarter was 5.80%, an increase of 0.41 percentage points year-on-year[12]

4、 用超募资金永久补充流动资金或归还银行贷款情况 □适用 √不适用 一、 股本变动情况 4、 公司认为必要或证券监管机构要求披露的其他内容 截至报告期末公司前十名境内存托凭证持有人情况表 □适用 √不适用 前十名有限售条件存托凭证持有人持有数量及限售条件 □适用 √不适用 (三)截至报告期末表决权数量前十名股东情况表 □适用 √不适用 (四) 战略投资者或一般法人因配售新股/存托凭证成为前十名股东 □适用 √不适用 □适用 √不适用 79 / 175 2023 年半年度报告 1 / 175 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确性、 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 五、 公司负责人彭博、主管会计工作负责人朱清 及会计机构负责人（会计主管人员）李春芳声 明：保证半年度报告中财务报告的真实、准确、完整。 八、 前瞻性陈述的风险声明 十、 是否存在违反规定决策程序对外提供担保的情况？ □适用 √不适用 目录 在本报告书中，除非文义另有所指，下列词语具有如下含义： | --- | --- | --- | |---------- ...

2023 年第一季度报告 证券代码：688016 证券简称：心脉医疗 2023 年第一季度报告 重要内容提示 第一季度财务报表是否经审计 一、 主要财务数据 本报告期比上年 1 / 13 | --- | --- | --- | --- | |-----------------------------------------------------------------------------------------|------------------|------------------|----------------------------------------| | 稀释每股收益（元/股） | | 1.73 | 0.58 | | 加权平均净资产收益率（%） | | 7.00 | 减少 0.92 个百分 点 | | 研发投入合计 | | 60,844,478.10 | 43.51 | | 研发投入占营业收入的比例 （%） | | 21.30 | 增加 4.86 个百分 点 | | | 本报告期末 | 上年度末 | 本报告期末比上 年度末增减变动 幅度 (%) | | 总资产 | 2,159,243, ...

2022 年年度报告 公司代码：688016 公司简称：心脉医疗 上海微创心脉医疗科技（集团）股份有限公司 2022 年年度报告 1 / 246 2022 年年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实性、准确性、 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司上市时未盈利且尚未实现盈利 □是 √否 三、 重大风险提示 公司已在本报告中详细描述可能存在的相关风险。具体内容详见本报告第三节"管理层讨论 与 分析"之"四、风险因素"，敬请广大投资者查阅。 四、 公司全体董事出席董事会会议。 五、 毕马威华振会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报告。 六、 公司负责人彭博、主管会计工作负责人朱清及会计机构负责人（会计主管人员）李春芳声明： 保证年度报告中财务报告的真实、准确、完整。 七、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 公司2022年度利润分配预案如下：公司拟以2022年度分红派息股权登记日的总股本为基数， 向全体股东每10股派发现金红利人民币23.00元（含税），预计共分配 ...

Financial Performance - The company's operating revenue for 2019 was approximately ¥333.73 million, representing a 44.39% increase compared to ¥231.13 million in 2018[18]. - The net profit attributable to shareholders for 2019 was approximately ¥141.76 million, a 56.38% increase from ¥90.65 million in 2018[18]. - The net cash flow from operating activities for 2019 was approximately ¥143.20 million, up 34.02% from ¥106.85 million in 2018[18]. - The total assets at the end of 2019 were approximately ¥1.16 billion, a 329.93% increase from ¥268.82 million at the end of 2018[18]. - The net assets attributable to shareholders at the end of 2019 were approximately ¥1.07 billion, a significant increase of 393.15% from ¥216.16 million at the end of 2018[18]. - The company achieved total revenue of ¥333,732,539.52, representing a year-on-year growth of 44.39%[91]. - The net profit attributable to the parent company was ¥141,755,858.84, an increase of 56.38% compared to the previous year[91]. - The sales revenue from the domestic market was ¥322,854,506.81, with a growth rate of 43.28% year-on-year[93]. - The gross profit margin for the main product category of arterial stents was 81.08%, an increase of 1.82 percentage points from the previous year[93]. - The company reported a significant increase in accounts receivable due to higher sales revenue, indicating strong demand for its products[148]. Research and Development - The company focuses on the research, production, and sales of interventional medical devices for aortic and peripheral vascular diseases, aiming to be a global leader in this field[23]. - The company has developed a comprehensive product line, including aortic stent graft systems and peripheral vascular stent systems, with a commitment to continuous innovation[23]. - The company has established a forward-looking R&D system to ensure continuous product innovation and efficient new product iteration[29]. - The company’s research and development strategy emphasizes producing one generation of products while developing another, ensuring a continuous pipeline of innovative products[50]. - The company’s innovative product development is expected to enhance its competitive edge in the increasingly fierce market[50]. - As of December 31, 2019, the company had 95 R&D personnel, accounting for 24.55% of total employees, with 56.84% holding master's degrees or higher[76]. - The company has invested a total of RMB 46.3 million in R&D during the reporting period, with ongoing projects including a multi-branch thoracic aortic stent system and drug balloon dilation catheter[73]. - The company submitted 32 patent applications and received 24 patent authorizations during the reporting period[81]. - The company is actively developing innovative products based on clinical needs and ongoing technology assessments[106]. Market Presence and Strategy - The company has established a strong market presence, covering 30 provinces and municipalities in China, and has collaborated with over 100 distributors[46]. - The company is focusing on expanding its marketing channels in second and third-tier cities, anticipating increased penetration of minimally invasive intervention treatments in these areas[46]. - The company operates on a distribution model, selling products to distributors who then sell to hospitals and medical institutions[58]. - The company expanded its market coverage by adding over 60 new hospitals, now reaching 300 hospitals with the Castor branched aortic stent and delivery system since its launch in 2017[110]. - The company plans to strengthen cooperation with leading regional clients globally and promote the certification of existing products in the EU and Asia-Pacific markets[185]. - The company will continue to strengthen its brand recognition in international markets to facilitate product entry into more countries and regions[185]. Financial Management and Governance - The company reported a government subsidy of approximately ¥15.98 million in 2019, compared to ¥8.24 million in 2018[20]. - The company plans to distribute a cash dividend of RMB 6.5 per 10 shares, totaling approximately RMB 46.79 million, based on a total share capital of 71.98 million shares as of December 31, 2019[168]. - The company commits to using at least 20% of the after-tax cash dividends received from the issuer in the previous fiscal year for stock repurchase if stock price stabilization measures are implemented[157]. - The company will prioritize cash dividends, ensuring that at least 20% of the distributable profits are allocated for cash dividends each year[167]. - The company’s profit distribution policy will maintain continuity and stability, considering industry characteristics and development stages[167]. - The company will enhance its governance structure and decision-making mechanisms to protect the interests of minority shareholders[163]. - The company has committed to not engaging in unfair benefit transfers or harming the interests of the company and its shareholders[178]. - The company will ensure compliance in related party transactions to protect the rights of the issuer and other shareholders[181]. - The company has a plan to enhance corporate governance and ensure compliance with its commitments[188]. Risks and Challenges - The company faced risks related to product price declines and technological updates, which could impact market performance[86][84]. - The company faces risks related to core competitiveness, including new product development and registration risks[114]. - The company’s procurement of raw materials is subject to foreign exchange fluctuations, which may impact operating performance[121]. Production and Operations - The production volume of arterial stents increased by 41.46% year-on-year, while the sales volume rose by 37.65%[95]. - The company aims to expand production capacity to meet increasing market demand and improve product quality while reducing costs[160]. - The company will continue to optimize existing business processes and implement information technology tools for efficient management[163]. - The company’s controlling shareholders committed to repurchase shares if any fraudulent issuance is confirmed, ensuring investor protection[141].

Financial Performance - The company's operating revenue for 2021 was approximately RMB 684.63 million, representing a year-on-year increase of 45.59% compared to RMB 470.25 million in 2020[4] - The net profit attributable to shareholders for 2021 was approximately RMB 315.86 million, reflecting a growth of 47.17% from RMB 214.61 million in 2020[4] - The net cash flow from operating activities for 2021 was approximately RMB 300.25 million, an increase of 38.09% compared to RMB 217.44 million in 2020[4] - The total assets of the company at the end of 2021 were approximately RMB 1.75 billion, a year-on-year increase of 27.43% from RMB 1.38 billion in 2020[4] - The net assets attributable to shareholders at the end of 2021 were approximately RMB 1.49 billion, reflecting a growth of 21.10% compared to RMB 1.23 billion in 2020[4] - The company's total operating costs were ¥150,281,289.69, up 52.91% year-over-year[85] - The gross profit margin decreased by 1.73 percentage points to 78.05%[86] - The company reported a net profit attributable to the parent company of ¥315,855,662.84, a year-over-year increase of 47.17%[107] Research and Development - The company is actively advancing the clinical trial phases for new products, including the next-generation Cratos branched aortic stent system and the Aegis abdominal aortic stent system, which have received necessary reports[10] - The company has a strong pipeline of innovative products, with ongoing upgrades to existing products and new technologies being developed to enhance its product line[9] - Research and development (R&D) investment totaled approximately ¥123.48 million, accounting for 18.04% of revenue, with a year-on-year increase of 48.20%[36] - The company has submitted a total of 140 patent applications, with 60 new patents granted during the reporting period, resulting in a total of 171 authorized patents as of December 31, 2021[36] - The company has launched 13 medical device products with registration certificates and 5 products with CE certification, establishing a comprehensive product line in the aortic and peripheral vascular intervention fields[32] - The company has initiated a series of R&D projects in the peripheral artery field, including peripheral milling tubes and vascular stents, which are progressing steadily[31] - The company emphasizes a market-oriented R&D mechanism to manage technological risks and ensure timely product updates and registrations[54] - The total R&D investment for the period was ¥123.48 million, reflecting a 48.20% increase from ¥83.32 million in the previous year[66] - The company is focusing on R&D investments, with new products like the Cratos branched aortic stent system and Aegis abdominal aortic stent system expected to enter clinical trials in 2022[156] Market Expansion - The company has expanded its international business, achieving over 100% growth in overseas sales revenue compared to the previous year, covering 18 countries and regions by the end of the reporting period[12] - The company has successfully expanded its international business, with sales covering 18 countries, including the UK and Brazil, where it achieved the first implant of its Minos abdominal aortic stent and delivery system[74] - The company achieved a market share ranking of second in China's aortic vascular intervention medical device market, only behind Medtronic, and first among domestic brands[59] - The company is actively pursuing market expansion strategies, targeting both domestic and international markets to increase its footprint[142] - The company aims to enhance product R&D and market expansion, focusing on the county-level hospital market to align with national healthcare resource strategies[130] Innovation and Technology - The company has received multiple awards for its technological innovations, including the Shanghai Science and Technology Progress Award and recognition as a "Manufacturing Industry Single Champion Product"[15] - The company is focused on continuous innovation and R&D investment, aiming to transition from technology followers to technology leaders in the medical device industry[16] - The company has developed advanced technologies such as ultra-low profile systems and precise release technology, enhancing the performance and safety of its vascular intervention products[33] - The company is exploring strategic partnerships to leverage synergies and enhance its competitive position in the market[143] - The company is committed to maintaining a competitive edge in the aortic and peripheral vascular intervention fields through continuous innovation and product development[129] Operational Efficiency - The company has established a complete quality management system in compliance with international standards, ensuring strict quality control across all operational stages[44] - The company has established a mature project evaluation system to track industry data and assess existing technologies to inform product development strategies[72] - The management team emphasized a commitment to maintaining high-quality standards while scaling production to meet growing demand[141] - The company has a strategic focus on expanding its market presence and improving operational efficiency through capacity expansion and cost reduction plans[157] Employee and Management - The company reported a total registered capital of 10,000 million RMB for Shanghai Blue Pulse and 5,500 million RMB for Shanghai Hongmai[151] - The total number of employees listed is 6, with a combined total compensation of RMB 1,800.35 million[167] - The company has a structured approach to employee compensation, with a focus on performance-based incentives[179] - The company has established a performance evaluation mechanism for senior management, linking their compensation to the achievement of operational goals[183] - The company reported a significant increase in R&D personnel, with key positions held by experienced professionals from various sectors, enhancing its innovation capabilities[141] Social Responsibility and Compliance - The company actively participates in social responsibility initiatives, including a poverty alleviation project in collaboration with the Gansu Yuanda Group[195] - The company has maintained compliance with information disclosure regulations, ensuring accurate and timely communication with investors[163] - The company has not been classified as a key pollutant discharge unit by environmental protection authorities[187] - The company received ISO 50001:2018 energy management system certification, recognizing its achievements in energy conservation and utilization[191] Future Outlook - Future plans include the application of smart manufacturing technologies to improve production efficiency and scale[132] - Future guidance indicates a projected revenue growth of 20% year-over-year, driven by increased market demand and successful product launches[143] - Overall, the company remains optimistic about its growth trajectory, supported by a robust pipeline of innovative products and strategic initiatives[143]

8 / 215 (一) 同时按照国际会计准则与按中国会计准则披露的财务报告中净利润和归属于上市公司股东 的净资产差异情况 □适用 √不适用 (二)同时按照境外会计准则与按中国会计准则披露的财务报告中净利润和归属于上市公司股东的 净资产差异情况 □适用 √不适用 (三) 境内外会计准则差异的说明： □适用 √不适用 | --- | --- | --- | --- | --- | --- | |-------|---------------------------------------------------------------------------------------------------------------------|---------------|------------------|---------------|---------------------| | | □不适用 | | | | 单位:元 币种:人民币 | | | 非经常性损益项目 | 2020 年金额 | 附注 （如适 用） | 2019 年金额 | 2018 年金额 | | | 非流动资产处置损益 | -40,942. ...

证券代码：688016 证券简称：心脉医疗 上海微创心脉医疗科技（集团）股份有限公司投资者关系活动记录表 编号：2022-002 | --- | --- | --- | |-------------------------|------------------------------|--------------------------------------------------------| | | □特定对象调研 □分析师会议 | | | 投资者关系活 | □媒体采访 | □业绩说明会 | | 动类别 | □新闻发布会 □路演活动 | | | | □现场参观 | | | | √其他 2022 | 年第一季度报告业绩电话会 | | 参与单位名称 及人员姓名 | 108 家机构 140 | 名参与人员，详见附件清单（排名不分先后） | | 时间 | 2022 年 4 月 30 日 | | | 地点 | 电话会议 | | | 上市公司接待 | | 朱清（董事兼总经理）、邱根永（副总经理兼董事会秘书）、 | | 人员姓名 | | 李春芳（财务总监）、刘昊（治疗方案推广资深总监） | | | | 一、问：目前， ...

2022 年第三季度报告 单位：元 币种：人民币 证券代码：688016 证券简称：心脉医疗 上海微创心脉医疗科技（集团）股份有限公 司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 本报告期 年初至报告期 | --- | --- | --- | --- | --- | |------------------------------------------------|----------------|------------------------------|----------------|--------------------- ...

上海微创心脉医疗科技（集团）股份有限公司 2022 年半年度报告 公司代码：688016 公司简称：心脉医疗 上海微创心脉医疗科技(集团)股份有限公司 2022 年半年度报告 二〇二二年八月 1 / 174 上海微创心脉医疗科技（集团）股份有限公司 2022 年半年度报告 重要提示 一、本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确性、 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、重大风险提示 本公司已在本报告中详细描述可能存在的相关风险。具体内容详见本报告第三节"管理层讨 论与分析"之"五、风险因素"，敬请广大投资者查阅。 三、未出席董事情况 未出席董事职务 未出席董事姓名 未出席董事的原因说明 被委托人姓名 董事 张俊杰 个人原因 彭博 四、本半年度报告未经审计。 五、公司负责人彭博、主管会计工作负责人朱清及会计机构负责人（会计主管人员）李春芳声明： 保证半年度报告中财务报告的真实、准确、完整。 六、董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 七、是否存在公司治理特殊安排等重要事项 □适用 √不适用 八、前瞻性陈述的风险 ...